Providing for cannabis; regulating the personal use and possession of cannabis; establishing the Cannabis Control Board; providing for powers and duties of the Cannabis Control Board; establishing the Cannabis Regulation Fund; providing for disproportionately impacted area, for regulation of cannabis business establishments, for enforcement and immunities, for laboratory testing, for advertising, marketing, packaging and labeling and for preparation, destruction and regulation of cannabis, edible and infused products; imposing a sales tax and excise tax on cannabis, edible and infused products; providing for cannabis clean slate and for miscellaneous provisions; imposing penalties; consolidating provisions relating to medical use of cannabis; transferring powers and duties of the Department of Health to the Cannabis Control Board; and making repeals.
HB1735 would create a comprehensive statewide framework for adult-use cannabis in Pennsylvania while also reorganizing and consolidating the existing medical cannabis program. The bill establishes the Cannabis Control Board as an independent regulator, transfers medical marijuana oversight from the Department of Health to that board, and sets up a detailed licensing system for cultivation centers, micro cultivation centers, dispensaries, testing labs, warehousing/distribution, and related agents. It legalizes possession and personal use for adults 21 and older within specified limits, while retaining restrictions on public use, impaired driving, school and correctional-facility use, and underage possession.
The bill also creates a tax and revenue structure for cannabis sales, including a 6% sales tax and an 8% excise tax, with revenue flowing to the Cannabis Regulation Fund, local governments, drug treatment and prevention, and the General Fund. It includes provisions for product testing, packaging, labeling, advertising, security, recordkeeping, and enforcement, as well as a clean slate section that would expunge certain nonviolent cannabis convictions and restore related driving and licensing privileges. The medical cannabis chapter is rewritten and continued, preserving patient access, caregiver rules, practitioner registration, dispensary operations, and research provisions.
The bill’s impact on state law would be substantial: it would decriminalize and regulate adult-use cannabis, repeal the current Medical Marijuana Act, amend the Controlled Substance, Drug, Device and Cosmetic Act, and override inconsistent provisions of existing law. It would also create new civil and criminal penalties for unauthorized cannabis activity, authorize local zoning and time-place-manner regulation within limits, protect lawful cannabis contracts and financial services, and provide employment and anti-discrimination protections with exceptions for safety-sensitive positions and federal-law conflicts. In addition, it would direct new grant and loan programs toward disproportionately impacted areas and small businesses, aiming to broaden participation in the cannabis market.
Overall, the bill appears designed as a full legalization-and-regulation package rather than a narrow policy change, with strong emphasis on public health, market oversight, social equity, and administrative control. Because no committee transcript or vote history was provided, there is no recorded legislative debate or roll-call sentiment to summarize from the available materials. Based on the text alone, the bill’s structure suggests a policy approach that tries to balance legalization with strict regulation, revenue generation, and expungement relief.
HB1735 would significantly revise Pennsylvania law by creating a new Cannabis Act, legalizing adult-use cannabis under state-regulated conditions, and replacing the existing Medical Marijuana Act with a reorganized medical cannabis chapter. It would shift regulatory authority to a new Cannabis Control Board, establish licensing and compliance rules for cannabis businesses, impose cannabis-specific taxes, and create a Cannabis Regulation Fund to receive and distribute revenue. The bill would also amend or repeal provisions of the Controlled Substance, Drug, Device and Cosmetic Act and related criminal statutes to align state law with the new cannabis framework.
No committee transcripts or vote history were provided, so there is no direct evidence of support, opposition, or amendment debate from the legislative record included here. From the bill text itself, the measure reflects a generally affirmative, reform-oriented approach to cannabis legalization and regulation, with extensive provisions for consumer access, business licensing, medical use, and expungement. The overall tone is policy-expansive but heavily regulated, suggesting an attempt to address both legalization goals and public-safety concerns.
The main likely points of contention are the scope of legalization, the creation of a new independent Cannabis Control Board, and the extent of regulatory and tax authority granted to the state. Other likely disputed issues include the treatment of existing medical cannabis operators, market-entry limits and preferences for disproportionately impacted areas and small businesses, employment protections versus employer drug-testing rights, local zoning authority, and the expungement of prior cannabis offenses. The bill also contains detailed rules on advertising, packaging, testing, and public use that could draw debate from public-health advocates, law enforcement, municipalities, employers, and cannabis industry stakeholders.